In silico design and search for acetylcholinesterase inhibitors in Alzheimer's disease with a suitable pharmacokinetic profile and low toxicity

Future Medicinal Chemistry

Volumn 3, Issue 8, 2011, Pages 947-960

  Da Silva, Vinicius Barreto ^a   De Andrade, Peterson ^a   Kawano, Daniel Fábio ^a   Morais, Pedro Alves Bezerra ^a   De Almeida, Jonathan Resende ^a   Carvalho, Ivone ^a   Taft, Carlton Anthony ^b   Da Silva, Carlos Henrique Tomich De Paula ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b CENTRO BRASILEIRO DE PESQUISAS FÍSICAS   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; MEMANTINE; RIVASTIGMINE; TACRINE;

ALZHEIMER DISEASE; CHROMOSOME DAMAGE; COMPUTER MODEL; DRUG BINDING SITE; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG SCREENING; FIRST PASS EFFECT; HUMAN; LIGAND BINDING; MUTAGENICITY; PHARMACOPHORE; PRIORITY JOURNAL; REVIEW; STRUCTURE ACTIVITY RELATION;

ACETYLCHOLINESTERASE; ALZHEIMER DISEASE; ANIMALS; CHOLINESTERASE INHIBITORS; DRUG DESIGN; HUMANS; MODELS, MOLECULAR;

EID: 79959793850     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.11.67     Document Type: Review

References (47)

1. Caltagirone C, Bianchetti A, di Luca M et al. Guidelinesforthe treatment of Alzheimer'sdisease from the italian association of psychogeriatrics. Drugs Aging 22, 1-26 (2005 (Pubitemid 41565869)
2. Holtzman DM. Alzheimer'sdisease: movingtowardsa vaccine. Nature 454, 418-420 (2008
3. Citron M. β-secretase asa target forthe treatment of Alzheimer'sdisease. J. Neurosci. Res. 70, 373-379 (2002)
4. MartinsRN, HallmayerJ. Age at onset: important markerof geneticheterogeneity in Alzheimer'sdisease. Pharmacogenomics J. 4, 138-140 (2004 (Pubitemid 38786550)
5. León R, de losRiosC, Marco-Contelles J et al. New tacrine-dihydropyridine hybridsthat inhibit acetylcholinesterase, calcium entry, andexhibit neuroprotection properties. Bioorg. Med. Chem. 16, 7759-7769 (2008
6. Wolfe MS. TherapeuticstrategiesforAlzheimer'sdisease. Nature Rev. Drug Discov. 1, 859 (2002
7. Samuelsson M, RambergV, Iverfeldn K. Alzheimeramyloid-β paptidesblock the activation of C/EBPb andC/EBPd in glialcells. Biochem. Bioph. Res. Co. 370, 619-622 (2008
8. WinklerJ, ThalLJ, Gage FH, FisherLJ. CholinergicstrategiesforAlzheimer'sdisease. J. Mol. Med. 76, 555-567 (1998
9. LléoA, GreenbergSM, Growdon JH. Current pharmacotherapy forAlzheimer'sdisease. Annu. Rev. Med. 57, 513-533 (2006
10. Mary A, RenkoDZ, Guillou C, ThalC. Potent acetylcholinesterase inhibitors: design, synthesis, andstructure-activity relationshipsof bis-interactingligandsin the galanthamine series. Bioorg. Med. Chem. 6 1835-1850 (1998
11. Liston DR, Nielsen JA, VillalobosAet al. Pharmacology of selective acetylcholinesterase inhibitors: implicationsforuse in Alzheimer'sdisease. Eur. J. Pharmacol. 486, 9-17 (2004 (Pubitemid 38130155)
12. Goedert M, andSpillantini MG. Acentury of Alzheimer'sdisease. Science 314, 777-781 (2006) .
13. Blennow K, de Leon MJ, ZetterbergH. Alzheimer'sdisease. Lancet 368, 387-403 (2006) .
14. Marco-ContellesJ, CarreirasMC, Rodrigues C, Villarroya M, Garcia AG. Synthesisandpharmacology of galanthamine. Chem. Rev. 106, 116-133 (2006
15. Maelicke A, SchrattenholzA, Samochocki M, Radina M, Albuquerque EX. Allosterically potentiatingligandsof nicotinicreceptorsasa treatment strategy forAlzheimer'sdisease. Behav. Brain Res. 113, 199-206 (2000 (Pubitemid 30645557)
16. WangD, Noda Y, Zhou Y et al. The allostericpotentiation of nicotinicacetylcholine receptorsby galanthamine amelioratesthe cognitive dysfunction in b amyloid25-30 i.c.v.-injectedmice: involvement of dopaminergicsystems. Neuropsychopharmacol. 32, 1261-1271 (2007
17. Schilström B, IvanovVB, WikerC, Svensson TH. Galanthamine enhancesdopaminergicneurotransmission in ivovia allostericpotentiation of nicotinicacetylcholine receptors. Neuropsychopharmacol. 32, 43-53 (2007
18. KrygerG, Silman I, Sussman JL. Three-dimensionalstructure of a complex of E2020 withacetylcholinesterase from Torpedocalifornica. J. Physiology 92, 191-194 (1998 (Pubitemid 29050932)
19. HarelM, Schalk I, Ehret-SabatierLet al. Quaternary ligandbindingtoaromaticresiduesin the active-site gorge of acetylcholinesterase. Proc. Natl Acad. Sci. 90, 9031-9035 (1993 (Pubitemid 23306445)
20. FelderCE, HarelM, Silman I, Sussman JL. Structure of a complex of the potent andspecificinhibitorBW284C51 withTorpedocalifornica acetylcholinesterase. Acta Crystallogr. D58, 1765-1771(2002
21. Akula N, Lecanu L, Greeson J, Papadopoulos V. 3D QSAR studiesof AchE inhibitorsbasedon moleculardockingscoresandCoMFA. Bioorg. Med. Chem. Lett. 16, 6277-6280 (2006 (Pubitemid 44709910)
22. Silva CHTP, CarvalhoI, Taft CA. Virtualscreening, molecularinteraction field, moleculardynamics, docking, density functionalandADMET propertiesof novelAChE inhibitorsin Alzheimer'sdisease. J. Biomol. Struct. Dyn. 24, 515-523 (2007
23. RollingerJM, Hornick A, LangerT, Stuppner H, Prast H. Acetylcholinesterase inhibitory activity of scopolin andscopoletin discoveredby virtualscreeningof naturalproducts. J. Med. Chem. 47, 6248-6254 (2004 (Pubitemid 39587249)
24. Roy KK, Dixit A, Saxena AK. An investigation of structurally diverse carbamatesforacetylcholinesterase (AChE) inhibition using3D-QSAR analysis. J. Mol. Graphics. Model. 27, 197-208 (2008) .
25. PyMOL, version 0.99. DeLanoScientificLLC, San Francisco, CA, USA(2006
26. Laurie ATR, Jackson RM, Q-SiteFinder: an energy-basedmethodforthe prediction of protein-ligandbindingsites. Bioinformatics 21, 1908-1916 (2005
27. Verdonk ML, Cole JC, Hartshorn MJ, Murray CW, TaylorRD. Improvedprotein- liganddockingusingGOLD. Proteins 52, 609-623 (2003
28. RichmondNJ, AbramsCA, Wolohan PRN, Abrahamian E, Willett P, Clark RD, GALAHAD: 1. Pharmacophore identification by hypermolecularalignment of ligandsin 3D. J. Comput. Aid. Mol. Des. 20, 567-587 (2006 (Pubitemid 44823892)
29. SYBYL, version 7.2. Tripos, Inc., St Louis, MO, USA(2006
30. Derek forWindows, version 10.0.2. Lhasa Ltd, Leeds, UK (2007
31. ADME Boxes, version 3.5. ACD/Labs, Toronto, Canada (2008
32. Bartolucci C, Perola E, PilgerC, FelsG, Lamba D. Three- dimensionalstructure of a complex of galanthamine (nivalin) withacetylcholinesterase from Torpedo californica: implicationsforthe design of new anti-Alzheimerdrugs. Proteins 42, 182-191 (2001 (Pubitemid 32047326)
33. Popa RV, Pereira EF, LopesC, Maelicke A, Albuquerque EX. The N-butylcarbamate derivative of galanthamine actsasan allostericpotentiatingligandon a7 receptorsin hippocampalneurons: clinicalimplicationsforthe treatment of Alzheimer'sdisease. J. Mol. Neurosci. 30, 227-232 (2006 (Pubitemid 46035374)
34. van de WaterbeemdH, GiffordE. ADMET in ilicomodeling: towardsprediction paradise? Nat. Rev. Drug Discov. 2, 192-204 (2003) (Pubitemid 37361664)
35. SeilerJP. Mutagenicity of benzimidazole andbenzimidazole derivatives. II. Incorporation of benzimidazole intothe nucleicacidsof Escherichia coli. Mutat. Res. 17, 21-25 (1973
36. SeilerJP. Mutagenicity of benzimidazole andbenzimidazole derivatives. IV. Molecularmechanism of benzimidazole mutagenicity. In vitro studieson transcription andtranslation. Biochem. Genet. 13, 635-641 (1975
37. SeilerJP, LimacherH. Mutagenicity of benzimidazole andbenzimidazole derivatives. III. Influence of the 2-substituent in benzimidazole on the mutagenicactivity. Chimia 27, 68-70 (1973
38. UteschD, Glatt H, OeschF. Rat hepatocyte-mediatedbacterialmutagenicity in relation tothe carcinogenicpotency of benz(a)anthracene, benzo(a)pyrene, andtwenty-five methylatedderivatives. Cancer Res. 47, 1509-1515 (1987
39. Andersen RA, EnomotoM, MillerEC, Miller JA. Carcinogenesisandinhibition of the Walker256 tumorin the rat by trans-4-acetamidostilbene, itsN-hydroxy metabolite, andrelatedcompounds. Cancer Res. 24, 128-143 (1964) .
40. Lagadic-Gossmann D, RisselM, Le Bot MA, GuillouzoA. Toxiceffectsof tacrine on primary hepatocytesandliverepithelialcellsin culture. Cell Biol. Toxicol. 14, 361-373 (1998 (Pubitemid 28467844)
41. Barratt MD, BasketterDA. Possible origin of the skin sensitization potentialof isoeugenolandrelatedcompounds. (I) Preliminary studiesof potentialreaction mechanisms. Contact Dermatitis 27, 98-104 (1992) .
42. BasketterDA, Flyvholm MA, Menne T. Classification criteria forskin-sensitizingchemicals: a commentary. Contact Dermatitis 40, 175-182 (1999
43. Wilkinson GR. Pharmacokinetics: the dynamicsof drugabsorption, distribution, andelimination. In: Goodman and Gilman's The Pharmacological Basis of Therapeutics (10th EditionHardman JG, LimbirdLE, Gilman AG (EdsMcGraw-Hill, NY, USA3-29 (2001
44. KernsE, Li D. Drug-like properties: concepts, structure design, andmethodsfrom ADME totoxicity optimization. Eur. J. Drug Metab. Pharmacokinet. 33, 61-62 (2008
45. van de WaterbeemdH, HansLennernasH, PerArtursson PH. Drug Bioavailability: Estimation of Solubility, Permeability, Absorption and Bioavailability. Wiley-VCH, Weinheim, Germany (2003
46. Scott LJ, Goa KL. Galanthamine: a review of itsuse in Alzheimer'sdisease. Drugs 60, 1095-1122 (2000
47. Patrick GL. An Introduction to Medicinal Chemistry. OxfordUniversity Press, Oxford, UK (2005).